If this Pokémon moved from your Bench to the Active Spot this turn, this attack does 90 more damage.
Ascended Heroes was released in 2026. Series classification for this set is Mega Evolution.
The checklist contains 295 cards, placing it in a very large expansion range. As of this year, it is one of the newest tracked releases.
Within this set, Rayquaza is card number 153 with a Rare designation.
In 2026, Ascended Heroes introduced this print of Rayquaza. Its card type is Pokémon., The rarity label is Rare., Printed HP is 120., and Energy typing is Dragon.
It carries a Basic Stage subtype designation. The printed attacks highlight "Breakthrough Assault" and "Dragon Claw".
It requires 1 energy to retreat. Within set composition, this rarity normally lands above common and uncommon print tiers.
Rayquaza (Ascended Heroes) is presently valued at about $0.29 in raw condition. Its 7-day trend is positive, up 3.6%.
Versus its 30-day baseline of $0.34, this card is now 15.2% lower. In the past 90 days, observed prices ranged from $0.26 to $0.49 (79% spread), a high-volatility profile.
The listed rarity for this print is Rare.
A wider Rayquaza checklist helps contextualize this specific Rayquaza print. The current sample spans 6 comparable cards from 5 sets.
In this sample, pricing ranges between $0.85 and $51.67 (5979% total span). Relative to the alternative average ($20.47), this card is -99%.
Notable alternatives include Rayquaza #XY64 (XY Black Star Promos) at $27.95, Rayquaza #XY141 (XY Black Star Promos) at $24.86, Rayquaza #SWSH029 (SWSH Black Star Promos) at $4.62, and Rayquaza #138 (Vivid Voltage) at $12.86.
Collector-focused market read: Weekly movement is positive (3.6%), and value remains materially above its recent low (12%). Observed 90-day bounds of $0.26 and $0.49 create a 79% band, matching a high-volatility profile.
Current value is 15.2% below its 30-day reference ($0.34). No consistent graded benchmark is available in this snapshot, so condition-adjusted pricing should be reviewed with active listings.
